Carfilzomib, Lenalidomide, and Dexamethasone for Relapsed Multiple Myeloma
Open accessThe DOI matches its Crossref record; 34 of the 34 references it cites were found in a registry or an index.
Abstract
BACKGROUND: Lenalidomide plus dexamethasone is a reference treatment for relapsed multiple myeloma. The combination of the proteasome inhibitor carfilzomib with lenalidomide and dexamethasone has shown efficacy in a phase 1 and 2 study in relapsed multiple myeloma. METHODS: We randomly assigned 792 patients with relapsed multiple myeloma to carfilzomib with lenalidomide and dexamethasone (carfilzomib group) or lenalidomide and dexamethasone alone (control group). The primary end point was progression-free survival. RESULTS: Progression-free survival was significantly improved with carfilzomib (median, 26.3 months, vs. 17.6 months in the control group; hazard ratio for progression or death, 0.69; 95% confidence interval [CI], 0.57 to 0.83; P=0.0001). The median overall survival was not reached in either group at the interim analysis. The Kaplan-Meier 24-month overall survival rates were 73.3% and 65.0% in the carfilzomib and control groups, respectively (hazard ratio for death, 0.79; 95% CI, 0.63 to 0.99; P=0.04). The rates of overall response (partial response or better) were 87.1% and 66.7% in the carfilzomib and control groups, respectively (P<0.001; 31.8% and 9.3% of patients in the respective groups had a complete response or better; 14.1% and 4.3% had a stringent complete response). Adverse events of grade 3 or higher were reported in 83.7% and 80.7% of patients in the carfilzomib and control groups, respectively; 15.3% and 17.7% of patients discontinued treatment owing to adverse events. Patients in the carfilzomib group reported superior health-related quality of life. CONCLUSIONS: In patients with relapsed multiple myeloma, the addition of carfilzomib to lenalidomide and dexamethasone resulted in significantly improved progression-free survival at the interim analysis and had a favorable risk-benefit profile. (Funded by Onyx Pharmaceuticals; ClinicalTrials.gov number, NCT01080391.).
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“The KRd regimen has been shown to be effective in a randomized trial, and is a major option for the treatment of relapsed disease (Table 8).67”
From Multiple myeloma: 2024 update on diagnosis, risk-stratification, and management (2024) · cites this paper as [67]
In the citing paper
“Daratumumab with lenalidomide and dexamethasone was associated with clinically manageable adverse events that were consistent with the known toxic effects of lenalidomide and dexamethasone 27,28,30,31 and of daratumumab.9,10”
From Daratumumab, Lenalidomide, and Dexamethasone for Multiple Myeloma. (2016) · cites this paper as [27]
In the citing paper
“Pomalidomide is most often used in combination with dexamethasone, either alone or as part of triplet regimens with a variety of other anti-myeloma agents, including bortezomib45, daratumumab46 or elotuzumab47.”
From Cancer therapies based on targeted protein degradation — lessons learned with lenalidomide (2021) · cites this paper as [46]
Citations
Cites
Aaronson, N. K., Ahmedzai, S., Bergman, B., Bullinger, M., Cull, A., Duez, N. J., Filiberti, A., Flechtner, H., Fleishman, S. B., Haes, J. C. J. M. D., et al. (1993) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/85.5.365 · Cited by 16,005
International uniform response criteria for multiple myeloma
Durie, B. G. M., Harousseau, J.-L., Miguel, J. S., Bladé, J., Barlogie, B., Anderson, K., Gertz, M., Dimopoulos, M., Westin, J., Sonneveld, P., et al. (2006) · Leukemia · doi:10.1038/sj.leu.2404284 · Cited by 2,632
Self-citationDiscrete sequential boundaries for clinical trials
GORDON LAN, K. K., & DEMETS, D. L. (1983) · Biometrika · doi:10.1093/biomet/70.3.659 · Cited by 2,310 · cited 2×
“The standard-risk group consisted of patients without t(4;14) or t(14;16) and with deletion 17p in less than 60% of plasma cells.”
BackgroundDiscrete Sequential Boundaries for Clinical Trials
Lan, K. K. G., & DeMets, D. L. (1983) · Biometrika · doi:10.2307/2336502 · Cited by 2,310
Improved survival in multiple myeloma and the impact of novel therapies
Kumar, S. K., Rajkumar, S. V., Dispenzieri, A., Lacy, M. Q., Hayman, S. R., Buadi, F. K., Zeldenrust, S. R., Dingli, D., Russell, S. J., Lust, J. A., et al. (2008) · Blood · doi:10.1182/blood-2007-10-116129 · Cited by 2,240
Self-citationBladÉ, J., Samson, D., Reece, D., Apperley, J., BJÖrkstrand, B., Gahrton, G., Gertz, M., Giralt, S., Jagannath, S., Vesole, D., et al. (1998) · British Journal of Haematology · doi:10.1046/j.1365-2141.1998.00930.x · Cited by 1,519
Lenalidomide plus Dexamethasone for Relapsed or Refractory Multiple Myeloma
Dimopoulos, M., Spencer, A., Attal, M., Prince, H. M., Harousseau, J.-L., Dmoszynska, A., Miguel, J. S., Hellmann, A., Facon, T., Foà, R., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070594 · Cited by 1,450
Self-citationLenalidomide plus Dexamethasone for Relapsed Multiple Myeloma in North America
Weber, D. M., Chen, C., Niesvizky, R., Wang, M., Belch, A., Stadtmauer, E. A., Siegel, D., Borrello, I., Rajkumar, S. V., Chanan-Khan, A. A., et al. (2007) · New England Journal of Medicine · doi:10.1056/nejmoa070596 · Cited by 1,233
Self-citationLenalidomide Maintenance after Stem-Cell Transplantation for Multiple Myeloma
Attal, M., Lauwers-Cances, V., Marit, G., Caillot, D., Moreau, P., Facon, T., Stoppa, A. M., Hulin, C., Benboubker, L., Garderet, L., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114138 · Cited by 1,155
Self-citationLenalidomide after Stem-Cell Transplantation for Multiple Myeloma
McCarthy, P. L., Owzar, K., Hofmeister, C. C., Hurd, D. D., Hassoun, H., Richardson, P. G., Giralt, S., Stadtmauer, E. A., Weisdorf, D. J., Vij, R., et al. (2012) · New England Journal of Medicine · doi:10.1056/nejmoa1114083 · Cited by 1,147
Cited by
Items 901–1,000 of 1,000
Gao, Y., Zhou, D., Bai, X. F., Wang, Y., Wang, C., & Bi, L. (2025) · Frontiers in Pharmacology · doi:10.3389/fphar.2025.1570017 · Cited by 7
Practical guidance for new multiple myeloma treatment regimens: A nursing perspective
Epstein, M., & Morrison, C. (2022) · Seminars in Oncology · doi:10.1053/j.seminoncol.2022.01.010 · Cited by 5
Supportive care in multiple myeloma
Jurczyszyn, A. J., Charliński, G., & Vesole, D. H. (2022) · Acta Haematologica Polonica · doi:10.5603/ahp.a2022.0031 · Cited by 7
Carfilzomib-Loaded Ternary Polypeptide Nanoparticles Stabilized by Polycationic Complexation
Agbana, P., Park, J. E., Rychahou, P. G., Kim, K., & Bae, Y. (2023) · Journal of Pharmaceutical Sciences · doi:10.1016/j.xphs.2023.08.026 · Cited by 5
Barilà, G., Quaglia, F. M., Furlan, A., Pescosta, N., Bonalumi, A., Marcon, C., Pascarella, A., Tinelli, M., March, E. D., Liço, A., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05443-8 · Cited by 5
Goudarzi, Z., Shahtaheri, R. S., Najafpour, Z., Hamedifar, H., & Ebrahimi, H. (2024) · Cost Effectiveness and Resource Allocation · doi:10.1186/s12962-024-00525-4 · Cited by 5
The characteristics of patients with multiple myeloma surviving over 10 years
Huang, B., Zhang, H., Liu, J., Gu, J., Chen, M.-L., Kuang, L., Li, X., & Li, J. (2024) · Frontiers in Oncology · doi:10.3389/fonc.2024.1490630 · Cited by 5
Novel combination approaches for myeloma
Lonial, S., & Nooka, A. K. (2015) · Hematology · doi:10.1182/asheducation-2015.1.286 · Cited by 5
Salvage therapies in relapsed and/or refractory myeloma: what is current and what is the future?
Thumallapally, N., Yu, H., Asti, D., Vennepureddy, A., & Terjanian, T. (2016) · OncoTargets and Therapy · doi:10.2147/ott.s110189 · Cited by 5
Should minimal residual disease negativity not be the end point of myeloma therapy?
Sonneveld, P. (2017) · Blood Advances · doi:10.1182/bloodadvances.2017000109 · Cited by 5
Therapy for relapsed multiple myeloma
Aljama, M. A., Sidiqi, M. H., & Dingli, D. (2018) · Panminerva Medica · doi:10.23736/s0031-0808.18.03542-5 · Cited by 5
A Rare Case of Extramedullary Relapse of Multiple Myeloma Causing Bowel Obstruction
Bhardwaj, P. V., Khanna, S., Jawad, M. D., & Ali, S. S. (2019) · Case Reports in Hematology · doi:10.1155/2019/4962678 · Cited by 5
(KMMWP), T. K. M. M. W. P., Jo, J., Lee, H. S., Kım, K., Lee, J., Yoon, S., Bang, S., Kim, J. S., Eom, H., Yoon, D. H., et al. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03904-7 · Cited by 5
How I Treat Relapsed and/or Refractory Multiple Myeloma
Lee, H. C., & Cerchione, C. (2020) · Hematology Reports · doi:10.4081/hr.2020.8955 · Cited by 5
Delgado, J., Zienowicz, M., van Hennik, P. B., Moreau, A., Gisselbrecht, C., Enzmann, H. G., & Pignatti, F. (2021) · The Oncologist · doi:10.1002/onco.13892 · Cited by 5
“Furthermore, the addition of the second-generation IMiDs, lenalidomide [8] and pomalidomide [9], and the second-generation PIs carfilzomib [10] and ixazomib [11] provides additional within-class treatment options for patients with RR MM.”
BackgroundTeoh, P. J., An, Ö., Chung, T., Vaiyapuri, T. S., Raju, A., Hoppe, M. M., Toh, S. H. M., Wang, W., Chan, M. C., Fullwood, M. J., et al. (2022) · Oncogene · doi:10.1038/s41388-022-02227-8 · Cited by 5
Polypharmacology in Old Drug Rediscovery: Drug Repurposing
Wang, Z., & Yang, B. (2022) · Springer eBooks · doi:10.1007/978-3-031-04998-9_13 · Cited by 7
Jang, H. Y., Lee, H. K., Kim, C. J., Yoon, S., Kim, I., & Oh, J. M. (2022) · International Journal of Environmental Research and Public Health · doi:10.3390/ijerph192013560 · Cited by 5
“Second, most of the studies of carfilzomib were performed on white populations [5,9,10,16,17], and the safety of minority populations were not discussed.”
BackgroundMethodResultInfluentialKhan, A., Ozga, M. P., Bhatt, H., Faisal, M. S., Ansari, S., Zhao, Q., Bumma, N., Cottini, F., Devarakonda, S. S., Rosko, A. E., et al. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.12.001 · Cited by 5
Antonioli, E., Pilerci, S., Attucci, I., Buda, G., Gozzetti, A., Candi, V., Simonetti, F., Giudice, M. L. D., Ciofini, S., Staderini, M., et al. (2023) · Frontiers in Oncology · doi:10.3389/fonc.2023.1162990 · Cited by 5
“3 months) when compared with the control arm receiving Rd (2).”
Horigome, Y., Iino, M., Harazaki, Y., Kobayashi, T., Handa, H., Hiramatsu, Y., Kuroi, T., Tanimoto, K., Matsue, K., Abe, M., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05428-7 · Cited by 5
Laribi, K., Leleu, X. P., Texier, N., Germain, R., Touzeau, C., Hammoud, M., Payssot, A., Schulmann, S., Calloch, R. L., Trebouet, A., et al. (2023) · eJHaem · doi:10.1002/jha2.828 · Cited by 5
“The 78.4% ORR rate and 59.2% of VGPR are consistent with data reported in the literature ranging for the latter between 50 and 70% [5, 7–9].”
BackgroundResultInfluentialGarcía‐Guiñón, A., Charry, P. A., Lorenzo, M.-J. J., Sarrà, J., Delgado, I., de la Torre, L. S., Santaliestra, M., García‐Pintos, M., Gonzalez, Y., Senín, A., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06240-1 · Cited by 5
A myeloma multiplex megközelítése Magyarországon 2016-ban
Varga, G., Mikala, G., Váróczy, L., & Illés, Á. (2016) · Orvosi Hetilap · doi:10.1556/650.2016.30341 · Cited by 14
Kadhem, S., Ebrahem, R., Cooper, S., Manlove, E., & Lee, R. (2017) · Cureus · doi:10.7759/cureus.1041 · Cited by 5
Prevention and treatment of relapse after stem cell transplantation in lymphoid malignancies
Sureda, A. M., Dreger, P., Bishop, M. R., Kröger, N. M., & Porter, D. (2018) · Bone Marrow Transplantation · doi:10.1038/s41409-018-0214-5 · Cited by 5
Munshi, N. C., & Jagannath, S. (2017) · Elsevier eBooks · doi:10.1016/b978-0-323-35762-3.00086-x · Cited by 6
Barth, P. M., Vale, C. A., Chambers, A. B., & Reagan, J. L. (2018) · Future Oncology · doi:10.2217/fon-2017-0722 · Cited by 5
Senín, A., García‐Pallarols, F., Azaiz, R. B., Martínez, L., Montesdeoca, S., Roman-Bravo, D., Ferraro, M. P., Párraga, I., Besses, C., & Abella, E. (2019) · Annals of Hematology · doi:10.1007/s00277-019-03601-5 · Cited by 6
Huang, L., Wong, S. W. K., Andreadis, C. B., & Olin, R. L. (2019) · Current Oncology Reports · doi:10.1007/s11912-019-0778-2 · Cited by 7
Abe, Y., Kobayashi, T., Narita, K., Kobayashi, H., Kitadate, A., Miura, D., Takeuchi, M., & Matsue, K. (2019) · Blood Advances · doi:10.1182/bloodadvances.2019000247 · Cited by 5
Scheid, C., Blau, I. W., Sellner, L., Ratsch, B. A., & Basic, E. (2020) · European Journal Of Haematology · doi:10.1111/ejh.13523 · Cited by 5
Xavier, F. D., Ferreira, F. S. B., & Abreu, R. M. (2020) · Oncotarget · doi:10.18632/oncotarget.27819 · Cited by 5
“…for elderly patients) or interruption of steroids in patients in complete remission, change the treatment administration schedule to one with a lower frequency, change daratumumab to every 4 weeks instead of every 2 weeks after the initial 8-week weekly administration, in www.oncotarget.com…”
Duarte, P. J., Schutz, N. P., Ochoa, P. A., Yantorno, S., Orlando, S., Lopresti, S., Zabaljauregui, S., Aizpurua, F., Shanley, C. M., Giannini, E., et al. (2021) · Expert Review of Hematology · doi:10.1080/17474086.2021.1886073 · Cited by 5
MacEwan, J. P., Majer, I. M., Chou, J. W., & Panjabi, S. S. (2021) · Therapeutic Advances in Hematology · doi:10.1177/20406207211027463 · Cited by 5
“3,8,28 Moreover, only 20% of patients in ASPIRE were recruited from North America, while SEER data are entirely from the US (and not entirely representative of the US population).”
Kawaji‐Kanayama, Y., Muramatsu, A., Sasaki, N., Shimura, K., Kiyota, M., Fuchida, S., Isa, R., Fujino, T., Matsumura‐Kimoto, Y., Tsukamoto, T., et al. (2022) · International Journal of Hematology · doi:10.1007/s12185-021-03262-z · Cited by 5
Yoroidaka, T., YAMASHITA, T., Murata, R., Yoshihara, K., Yoshihara, S., Ueda, M., Nakao, S., Matsue, K., & Takamatsu, H. (2022) · Anticancer Research · doi:10.21873/anticanres.16145 · Cited by 5
Cardiovascular Toxicity in Cancer Therapy: Protecting the Heart while Combating Cancer
Manhas, A., Tripathi, D., Thomas, D., & Sayed, N. (2024) · Current Cardiology Reports · doi:10.1007/s11886-024-02099-2 · Cited by 6
“Despite the extensive clinical use of PIs [83], there are still significant gaps in understanding their cardiovascular toxic events, which can be explored using hiPSC technology ( Fig.”
Manier, S., de la Contrie, M. D. C., Hieulle, J., Daniel, A., & Facon, T. T. F. (2019) · La Presse Médicale · doi:10.1016/j.lpm.2019.07.023 · Cited by 7
Suzuki, K., Nishiwaki, K., Gunji, T., Katori, M., Masuoka, H., & Yano, S. (2020) · Cancer Medicine · doi:10.1002/cam4.2828 · Cited by 5
Therapy Sequencing Strategies in Multiple Myeloma: Who, What and Why?
Costello, C. L., & Mikhael, J. R. (2017) · Future Oncology · doi:10.2217/fon-2017-0493 · Cited by 5
Evolving Paradigms of Therapy for Multiple Myeloma: State of the Art and Future Directions
Goldsmith, S. R., & Vij, R. (2021) · JCO Oncology Practice · doi:10.1200/op.21.00210 · Cited by 5
Molecular and immunological determinants of long-term survival in multiple myeloma
Kasomva, K., Yadav, K., Janz, S., Dhakal, B., & Rao, S. (2025) · Blood Advances · doi:10.1182/bloodadvances.2025016829 · Cited by 4
Multiple Myeloma: 2026 Update on Diagnosis, Risk‐Stratification and Management
Rajkumar, S. V. (2026) · American Journal of Hematology · doi:10.1002/ajh.70475 · Cited by 5
Self-citationAn update in treatment options for multiple myeloma in nontransplant eligible patients
Broijl, A., & Sonneveld, P. (2015) · Expert Opinion on Pharmacotherapy · doi:10.1517/14656566.2015.1075507 · Cited by 4
“The recently published ASPIRE trial compared carfilzomib added to lenalidomide and dexamethasone (CRd) versus lenalidomide and dexamethasone (Rd) in relapsed MM having received one to three prior lines of therapy [13].”
BackgroundMethodDoran, S. L., Mysore, M. M., Kassaian, S. E., Kotloff, E. D., Kamangar, F., Emadi, A., Apata, J., & Barr, B. (2023) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2023.1129943 · Cited by 4
Yang, T.-L., Lin, C. S., Ho, C., Huang, T., Wu, Y., Jhou, H., Chen, P., & Lee, C. (2023) · Life · doi:10.3390/life13122259 · Cited by 4
Abdi, J., & Nasr, P. (2025) · Frontiers in Hematology · doi:10.3389/frhem.2025.1435193 · Cited by 4
Management of high-risk Myeloma: an evidence-based review of treatment strategies
Lehners, N., Hayden, P. J., Goldschmidt, H., & Raab, M. S. (2016) · Expert Review of Hematology · doi:10.1080/17474086.2016.1204908 · Cited by 4
“reporting a median PFS of 26 months with the median OS not yet reached after a median follow-up of 32 months [85].”
Treatment of Relapsed Myeloma in a Patient With Renal Insufficiency
Bladé, J., Rosiñol, L., Cibeira, M. T., & de Larrea, C. F. (2018) · Journal of Clinical Oncology · doi:10.1200/jco.2017.77.6419 · Cited by 4
Self-citationTan, T., Hong, Y., Li, S., Yu, J., Sung, Y.-C., Wang, P.-N., & Teng, C. J. (2020) · The Chinese Journal of Physiology · doi:10.4103/cjp.cjp_68_20 · Cited by 4
Treatment Induced Cytotoxic T-Cell Modulation in Multiple Myeloma Patients
Barilà, G., Pavan, L., Vedovato, S., Berno, T., Schirico, M. L., Febbo, M. A., Teramo, A., Calabretto, G., Vicenzetto, C., Gasparini, V. R., et al. (2021) · Frontiers in Oncology · doi:10.3389/fonc.2021.682658 · Cited by 5
Loponen, H., Mehtälä, J., Ylisaukko‐oja, T., Brück, O. E., Porkka, K., Koskenvesa, P., Saukkonen, K., & Lievonen, J. (2023) · eJHaem · doi:10.1002/jha2.802 · Cited by 4
Hematologists’ awareness of venous thromboembolism in multiple myeloma: a national survey in China
Li, Q., Zhang, B., Cheng, Q., Zhao, F., Li, J., Yan, H., Xu, A., Sun, C., & Hu, Y. (2023) · Annals of Medicine · doi:10.1080/07853890.2023.2263019 · Cited by 4
“…endothelial cells was much more powerful than bortezomib, which can only be effectively prevented by low-dose rivarox-aban rather than aspirin [7,24]. altogether, MM patients receiving thrombogenic drugs, including iMiDs-doxorubicin combination chemotherapy, and carfilzomib-containing regimen,…”
BackgroundThromboprophylaxis in multiple myeloma: a case-based review with practical guidelines
Charalampous, C. M., Shah, D., Kumar, S. K., & Chakraborty, R. (2024) · Annals of Hematology · doi:10.1007/s00277-024-05733-9 · Cited by 4
“The addition of carfilzomib in the ASPIRE study reported 6.6% DVT events in the KRd cohort and 3.9% in the lenalid - omide and dexamethasone group [64].”
InfluentialWu, W., Tang, F., Wang, Y., Yang, W., Zhao, Z., Gao, Y., & Dong, H. (2025) · Health Economics Review · doi:10.1186/s13561-025-00611-0 · Cited by 4
Minařík, J., Pour, L., Látal, V., Jelínek, T., Štraub, J., Jungová, A., Radocha, J., Pavlíček, P., Štork, M., Pika, T., et al. (2025) · BMC Cancer · doi:10.1186/s12885-025-14087-y · Cited by 4
Self-citationLeypoldt, L. B., Guo, L., Besemer, B., Hänel, M., Raab, M. S., Mann, C., Michel, C. S., Reinhardt, H. C., Blau, I. W., Görner, M., et al. (2025) · Cardio-Oncology · doi:10.1186/s40959-025-00358-x · Cited by 5
Rizzello, I., Sacchetti, I., Barbato, S., Solli, V., Stefanoni, P., Cani, L., Quaresima, M., Belotti, A., Sgherza, N., Gentile, M., et al. (2025) · Clinical and Experimental Medicine · doi:10.1007/s10238-025-01956-w · Cited by 4
“His-torically, first choice for second-line therapy included len-based triplets (i.e., carfilzomib–lenalidomide–dexamethasone [KRd], daratumumab–lenalidomide–dexamethasone [DaraRd], ixazomib–lenalidomide–dexamethasone [IRd], or elotuzumab–lenalidomide–dexamethasone [EloRd]) [2–5].”
Zagouri, F., Ρούσσου, Μ., Kastritis, E., Gavriatopoulou, M., Eleutherakis‐Papaiakovou, E., Kanellias, N., Kalapanida, D., Christoulas, D., Migkou, M., Terpos, E., et al. (2016) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2016.1151513 · Cited by 4
“Registration studies have used high-dose dexamethasone in combination with lenalidomide;[2,3] however, low-dose dexamethasone is used in almost all large prospective phase-II or phase-III studies in which the comparator is lenalidomide with dexamethasone,[16,17] and it has become common practice to administer dexameth…”
BackgroundSelf-citationVision Statement for Multiple Myeloma: Future Directions
Anderson, K. C. (2016) · Cancer treatment and research · doi:10.1007/978-3-319-40320-5_2 · Cited by 4
“Bortezomib has already provided the framework for the development of second generation proteasome inhibitors carfilzomib [45, 46, 49], ixazomib [10, 30, 39], and marizomib [7, 9, 15], and also led to ongoing current efforts to target the ubiquitin proteasome cascade upstream of the proteasome with inhibitors of deubiq…”
BackgroundSethi, T. K., Basdag, B., Bhatia, N., Moslehi, J. J., & Reddy, N. M. (2017) · Current Hematologic Malignancy Reports · doi:10.1007/s11899-017-0369-y · Cited by 5
Yang, E. H., Courtney, C., Garg, V., Fradley, M. G., & Schiller, G. J. (2018) · Cardio-Oncology · doi:10.1186/s40959-018-0028-z · Cited by 4
Heitner, S. B., Minnier, J., Naher, A., Woerkom, R. C. V., Ritts, A. J., Ferencik, M., Broberg, C. S., Medvedova, E., Silbermann, R. W., & Scott, E. C. (2018) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2018.08.004 · Cited by 4
Osafehinti, D. A., & Zivari, K. (2019) · Case Reports in Hematology · doi:10.1155/2019/5180424 · Cited by 5
“*e US FDA recently approved the combination of carfilzomib (Kyprolis), a proteasome inhibitor, lenalidomide (Revlimid), a synthetic derivative of thalidomide [7], and dexamethasone for patients with relapsed/refractory multiple myeloma after reports showed better survival outcomes compared to earlier regimens [8, 9].”
BackgroundResultInfluentialClinical Efficacy of Daratumumab in Monotherapy of Relapsed/Refractory Multiple Myeloma
Бессмельцев, С. С., Karyagina, E. V., Ilyushkina, E., Столыпина, Ж. Л., Рифкатовна, М. Р., Kostroma, I. I., & Шелковская, Т. Л. (2020) · Clinical oncohematology · doi:10.21320/2500-2139-2020-13-1-25-32 · Cited by 5
Pericardial relapse of multiple myeloma
Jamison, L. S., Mo, C. C., & Kwok, M. (2020) · BMJ Case Reports · doi:10.1136/bcr-2019-233340 · Cited by 4
[Patient-reported outcome and its application in hematological neoplasm].
Jiang, Q. (2019) · PubMed Central · doi:10.3760/cma.j.issn.0253-2727.2019.07.019 · Cited by 5
“[45] Stewart AK, Rajkumar SV, Dimopoulos MA, et al.”
BackgroundAbdallah, A.-O. A., Mohyuddin, G. R., Mahmoudjafari, Z., Atrash, S., Kawsar, H. I., Sigle, M., Shune, L. O., McGuirk, J. P., & Ganguly, S. (2020) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2020.08.026 · Cited by 4
Santoro, M., Romano, A., Mancuso, S., Siragusa, S. M., Raimondo, F. D., Martinelli, G., & Cerchione, C. (2021) · Panminerva Medica · doi:10.23736/s0031-0808.20.04133-6 · Cited by 4
Al‐Zoairy, R., Viveiros, A., Zoller, H., Schneeberger, S., Oberhuber, G., Gunsilius, E., Tilg, H., Wolf, D. G. F., & Rudzki, J. D. (2020) · Journal of Medical Case Reports · doi:10.1186/s13256-020-02511-9 · Cited by 4
Mexican Consensus of Multiple Myeloma
de la Peña-Celaya, J. A., Aguilar-Luévano, J., Alcivar-Cedeño, L. M., Álvarez-Vera, J. L., Anaya-Cuéllar, I., Añorve-Hernández, É., Arana-Luna, L. L., Arteaga-Ortíz, L., Baez-Islas, P. E., Banda-García, L. I., et al. (2020) · Gaceta Médica de México · doi:10.24875/gmm.m20000392 · Cited by 6
Giri, S., Chen, Y., Wu, J., Hageman, L., Richman, J., Francisco, L., Landier, W., Costa, L. J., McDonald, A. M., Murdaugh, D. L., et al. (2021) · Transplantation and Cellular Therapy · doi:10.1016/j.jtct.2021.06.014 · Cited by 4
Herrmann, J., Sahni, G., Gallardo, A., Spahillari, A., Galsky, M. D., Eschenhagen, T., Schaffer, W. L., Neilan, T. G., Ak, G., Donisan, T., et al. (2022) · Elsevier eBooks · doi:10.1016/b978-0-323-68135-3.00063-5 · Cited by 4
Wester, R., Dinmohamed, A. G., van der Holt, B., Zweegman, S., Minnema, M. C., Croockewit, S., Levin, M.-D., Libourel, E., de Waal, E., Sonneveld, P., et al. (2022) · HemaSphere · doi:10.1097/hs9.0000000000000683 · Cited by 4
van Beurden-Tan, C. H. Y., Sonneveld, P., & Groot, C. A. U. (2022) · BMC Cancer · doi:10.1186/s12885-022-09571-8 · Cited by 5
“The oldest included trial started in the year 2000 and the median follow-up ranged from 5·59 months (PANORAMA1 [18]) to 32·3 months (ASPIRE [19]).”
BackgroundDowney-Kopyscinski, S. L., Srinivasa, S., & Kisselev, A. F. (2022) · Scientific Reports · doi:10.1038/s41598-022-17239-3 · Cited by 4
Rezvani, A., Shahriarirad, R., Fallahi, M. J., & Zeighami, A. (2023) · Journal of Medical Case Reports · doi:10.1186/s13256-023-03765-9 · Cited by 4
“therapies were evaluated in the ASPIRE study [24].”
MethodMulti-omics analysis of multiple myeloma patients with differential response to first-line treatment
Zheng, B., Yi, K., Zhang, Y., Pang, T., Zhou, J.-Y., He, J., Lan, H., Xian, H., & Li, R. (2023) · Clinical and Experimental Medicine · doi:10.1007/s10238-023-01148-4 · Cited by 4
“Carfilzomib, the second-generation proteasome inhibitor showed promising efficacy in bortezomib-resistant MM cell lines and patients and the combination of mainly Carfilzomib, Lenalidomide and Dex-amethasone served as the second-line treatment [33], [34].”
BackgroundSanchez, L. J., Chari, A., Cheng, M., Cherepanov, D., DerSarkissian, M., Huang, F., Stull, D. M., Dabora, J., Young, M., Noga, S. J., et al. (2023) · Journal of Managed Care & Specialty Pharmacy · doi:10.18553/jmcp.2023.23031 · Cited by 6
Ixazomib: an oral proteasome inhibitor for the treatment of multiple myeloma
Shah, N., Biran, N., & Vesole, D. H. (2015) · Expert Opinion on Orphan Drugs · doi:10.1517/21678707.2016.1122516 · Cited by 4
“0001)].[16] In this trial, no significant difference was noted in PN in patients who received KRd compared to Rd (17.”
ResultMore convenient proteasome inhibition for improved outcomes
Auner, H. W., & Yong, K. (2018) · The Lancet Oncology · doi:10.1016/s1470-2045(18)30411-x · Cited by 4
The treatment of multiple myeloma in an era of precision medicine
Kint, N., Vlayen, S., & Delforge, M. (2019) · Expert Review of Precision Medicine and Drug Development · doi:10.1080/23808993.2019.1606672 · Cited by 4
“For instance, bortezomib is not optimal for patients with pre-existing peripheral neuropathy, whereas those with cardiovascular comorbidities will preferably not be treated with a carfilzomib-containing regimen [21,22].”
BackgroundKunacheewa, C., Feng, L., Manasanch, E. E., Bashir, Q., Patel, K. K., Mehta, R. S., Kaufman, G. P., Srour, S. A., Saini, N. Y., Iyer, S. P., et al. (2021) · British Journal of Haematology · doi:10.1111/bjh.17393 · Cited by 5
Klein, C. (2018) · MDPI eBooks · doi:10.3390/books978-3-03842-876-3 · Cited by 5
Cerchione, C., Lucignano, M., Pane, F., & Catalano, L. (2015) · European Journal Of Haematology · doi:10.1111/ejh.12705 · Cited by 4
Chim, C. S., Kumar, S. K., Orlowski, R. Z., Cook, G., Richardson, P. G. G., Gertz, M. A., Giralt, S., Mateos, M., Leleu, X. P., & Anderson, K. C. (2019) · Leukemia · doi:10.1038/s41375-019-0410-3 · Cited by 4
Self-citationKarp, S., Trautmann‐Grill, K., Warncke, P., Zolnowski, D., Röllig, C., Pannach, M., Zinn, J., Kroschinsky, F., Morgner, A., Bonin, M. V., et al. (2025) · Annals of Hematology · doi:10.1007/s00277-025-06262-9 · Cited by 4
Advances in NK cell therapy for multiple myeloma
Liu, N., Zeng, Y., Wang, Y., Wang, C., Li, N., & Xu, J. (2025) · Best Practice & Research Clinical Haematology · doi:10.1016/j.beha.2025.101639 · Cited by 3
Yu, S., Li, X., Peng, J., Wang, L., & Li, H. (2025) · Frontiers in Oncology · doi:10.3389/fonc.2025.1570981 · Cited by 3
CAR T-cells in multiple myeloma: the race to the start line
Bazarbachi, A. H., Bhutani, D., Hughes, M. S., Lentzsch, S., Mapara, M. Y., Muranski, P. J., Reshef, R., Wangjam, T., & Chakraborty, R. (2025) · Bone Marrow Transplantation · doi:10.1038/s41409-025-02787-9 · Cited by 3
ASPIRE for unprecedented benefit with carfilzomib in MM
Killock, D. (2014) · Nature Reviews Clinical Oncology · doi:10.1038/nrclinonc.2014.228 · Cited by 3
Beksaç, M., Seval, G. C., Koyun, D., Topçuoğlu, P., Yüksel, M. K., Gürman, G., & İlhan, O. (2022) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2022.12.007 · Cited by 3
Expert Council Review “Multiple myeloma”
Akhmedov, M., & Zeynalova, P. A. (2023) · Oncohematology · doi:10.17650/1818-8346-2023-18-2-10-16 · Cited by 3
Abe, Y., Sasaki, M., Takezako, N., Ito, S., Suzuki, K., Handa, H., Chou, T., Yoshida, T., Mori, I., Shinozaki, T., et al. (2023) · Annals of Hematology · doi:10.1007/s00277-023-05212-7 · Cited by 3
“1 3 higher number of regimens in our study (1 regimen: 49%; 2 regimens: 31%; 3 regimens: 18%; ≥4 regimens: 2%), compared with the phase 3 KRd study [17] (1 regimen: 46.”
BackgroundResultInfluentialDaratumumab Treatment for “Truly Frail” Elderly Myeloma Patients
Horigome, Y., Suzuki, K., & Suzuki, T. (2024) · Life · doi:10.3390/life14030389 · Cited by 4
“Rd) [65], ENDEAVOR (twice-weekly CFZ of 56 mg/m 2 and DEX [Kd56] vs. Vd) [66], and A.R.R.O.W. (once-weekly CFZ [70 mg/m 2 ]-DEX [Kd70] vs. CFZ [27 mg/m 2 ]-DEX [Kd27]) [67].”
Proteasome and PARP1 dual-target inhibitor for multiple myeloma: Fluzoparib
Deng, K., Li, Q., Lu, L., Wang, L., Cheng, Z., & Wang, S. Z. (2024) · Biochemistry and Biophysics Reports · doi:10.1016/j.bbrep.2024.101781 · Cited by 3
“Among them, the ubiquitin-proteasome degradation pathway in eukaryotes regulates many normal cellular processes [35].”
BackgroundCosta, L. J., Gay, F., Landgren, O., Mateos, M., Moreau, P., Touzeau, C., Ertel, F., McFadden, I., Najdi, R., & Weisel, K. C. (2025) · Annals of Hematology · doi:10.1007/s00277-024-06143-7 · Cited by 3
Self-citationNtanasis‐Stathopoulos, I., Malandrakis, P., Filippatos, C., Maganas, S., Fotiou, D., Theodorakakou, F., Spiliopoulou, V., Kanellias, N., Migkou, M., Eleutherakis‐Papaiakovou, E., et al. (2025) · Clinical Lymphoma Myeloma & Leukemia · doi:10.1016/j.clml.2025.08.003 · Cited by 3
Self-citationFaiman, B. M., & Valent, J. N. (2016) · Blood and Lymphatic Cancer Targets and Therapy · doi:10.2147/blctt.s90764 · Cited by 3
Metadata
- Authors
- Stewart, A. K., Rajkumar, S. V., Dimopoulos, M. A., Masszi, T., Špička, I., Oriol, A., Hájek, R., Rosiñol, L., Siegel, D. S., Mihaylov, G. G., Goranova-Marinova, V., Rajnics, P., Suvorov, A., Niesvizky, R., Jakubowiak, A. J., San-Miguel, J. F., Ludwig, H., Wang, M., Maisnar, V., Minarik, J., Bensinger, W. I., Mateos, M.-V., Ben-Yehuda, D., Kukreti, V., Zojwalla, N., Tonda, M. E., Yang, X., Xing, B., Moreau, P., & Palumbo, A.
- Affiliations
- Mayo Clinic in Arizona (US)
- Mayo Clinic (US)
- Alexandra Hospital (GR)
- Semmelweis University (HU)
- Josep Carreras Leukaemia Research Institute (ES)
- University of Ostrava (CZ)
- Hospital Clínic de Barcelona (ES)
- Hackensack University Medical Center (US)
- Queen Giovanna Hospital (BG)
- University Multipurpose Hospital for Active Treatment "Sveti Georgi" (BG)
- Somogy Megyei Kaposi Mór Oktató Kórház (HU)
- The First Republican Clinical Hospital of the Ministry of Health of the Udmurt Republic (RU)
- University of Chicago (US)
- Wilhelminen Hospital (AT)
- The University of Texas MD Anderson Cancer Center (US)
- Charles University (CZ)
- Fred Hutch Cancer Center (US)
- Princess Margaret Cancer Centre (CA)
- Université de Nantes (FR)
- University of Turin (IT)
- ORCID
- Venue
- New England Journal of Medicine
- Publisher
- Massachusetts Medical Society
- Published
- 2015-01-08
- Volume
- 372
- Issue
- 2
- Pages
- 142-152
- ISSN
- 0028-4793 (ISSN-L)
- 1533-4406
- OpenAlex
- W1985864219
- Semantic Scholar
- 6c229c6500f2d44efe03b42aea66351261666d13
- Cited by
- 1,332
- References
- 33
- Citations by year
- 2026: 36 · 2025: 62 · 2024: 63 · 2023: 79 · 2022: 112 · 2021: 137 · 2020: 149 · 2019: 131 · 2018: 166 · 2017: 168 · 2016: 148 · 2015: 77
- FWCI
- 93.38
- Type
- journal article
- Language
- en
- Open access
- bronze
- doi.org
- Locations
- New England Journal of Medicine (publishedVersion)
- PubMed (publishedVersion)
- CINECA IRIS Institutial research information system (University of Pisa) (submittedVersion)
- Dépôt institutionnel de l'Université libre de Bruxelles (Université Libre de Bruxelles) (submittedVersion)
- Institutional Research Information System University of Turin (University of Turin) (submittedVersion)
- Lirias (KU Leuven) (submittedVersion)
- Semmelweis University Repository (Semmelweis University) (submittedVersion)
- VUBIR (Vrije Universiteit Brussel) (submittedVersion)
- Topics
- Health Sciences › Medicine › Hematology › Multiple Myeloma Research and Treatments
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Protein Degradation and Inhibitors
- Health Sciences › Medicine › Oncology › Bone health and treatments
- Keywords
- carfilzomib, lenalidomide, dexamethasone, relapsed multiple myeloma, proteasome inhibitors, progression-free survival, overall survival, adverse events, health-related quality of life, combination therapy, treatment response, interim analysis, treatment discontinuation, stringent complete response, partial response, complete response, overall response rate
- MeSH terms
- Lenalidomide, Adult, Aged, Aged, 80 and over, Antineoplastic Combined Chemotherapy Protocols, Dexamethasone, Female, Humans, Male, Middle Aged, Multiple Myeloma, Oligopeptides, Recurrence, Thalidomide, Kaplan-Meier Estimate, Intention to Treat Analysis
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.